Cellectar Biosciences (CLRB) Capital Expenditures Growth (1y) (2012 - 2024)
Cellectar Biosciences (CLRB) Capital Expenditures Growth (1y) (2012 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1,133.33% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -37.81% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 142.64% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.37% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -73.62% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 22,433.30% |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -77.03% |
| Dec 31, 2023 | 126.34% |
| Dec 31, 2022 | -9.16% |
| Sep 30, 2022 | 73.91% |
| Dec 31, 2021 | 653.86% |
| Dec 31, 2020 | 200.61% |
| Jun 30, 2020 | 264.80% |
| Mar 31, 2020 | 69.06% |
| Dec 31, 2019 | -98.51% |
| Mar 31, 2019 | 338.04% |
| Mar 31, 2018 | -97.85% |
| Sep 30, 2017 | 2,392.20% |
| Jun 30, 2017 | 5,942.52% |
| Dec 31, 2016 | 258.58% |
| Sep 30, 2016 | -82.83% |
| Jun 30, 2016 | -48.69% |
| Dec 31, 2015 | 53.49% |
| Sep 30, 2015 | 177.52% |
| Mar 31, 2015 | 67.64% |
| Dec 31, 2014 | -5.32% |